Boothbay Fund Management, LLC Crispr Therapeutics Ag Transaction History

Boothbay Fund Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $464,096 - $867,387	12,017 Added 192.21%	18,269 $1.14 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $283,778 - $368,868	6,252 New	6,252 $283,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $211,601 - $335,984	-3,019 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $1.17 Million - $1.66 Million	-10,615 Reduced 77.86%	3,019 $338,000
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $1.2 Million - $1.92 Million	11,864 Added 670.28%	13,634 $2.21 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $195,974 - $371,770	1,770 New	1,770 $216,000
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $938,875 - $1.2 Million	-22,905 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $811,982 - $1.1 Million	22,905 New	22,905 $1.08 Million

503

57M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.03B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.